Literature DB >> 20026963

The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi.

Massimo Castellani1, Marco Carletto, Luca Baldini, Rossella Calori, Virgilio Longari, Davide Soligo, Luca Dellavedova, Paolo Gerundini.   

Abstract

PURPOSE: We assessed the prognostic value of F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow of patients with multiple myeloma (MM) in comparison with Tc-99m methoxy-isobutyl-isonitrile (MIBI).
METHODS: The extent and intensity of FDG and MIBI uptake in the bone marrow of 18 patients with a recent diagnosis of MM were assessed by visual score and by calculating the mean SUV (mSUV) for FDG and the femora/thigh ratio (TG/BKG, [Target/Background ratio]) for MIBI images. These parameters were correlated with clinical indexes of disease using hemoglobin and beta-2-microglobulin levels and plasma cell infiltrate (PCI) percentage. The mean values of the visual score, mSUV, and TG/BKG levels were compared in patients deceased after a relatively short follow-up (n = 9; group A) and in patients with a longer survival or were alive at the end of the study (n = 9; group B).
RESULTS: Significant correlations of mSUV and TG/BKG values with PCI percentages and beta-2-microglobulin were found (P < 0.05). The extent of FDG and MIBI bone marrow uptake was greater in patients of group A (P < 0.01). Higher values of mSUV (P < 0.01) and TG/BKG (P < 0.05) were also observed in patients of group A. These results were consistent with the differences (not statistically significant) in hemoglobin, albumin, beta-2-microglobulin levels, and PCI percentages observed in the 2 groups.
CONCLUSION: Our study demonstrates that an increase of FDG bone marrow uptake may predict a more aggressive disease, as much as MIBI uptake. Therefore, an additional analysis of FDG bone marrow images should be performed in patients undergoing PET studies during the initial staging of MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20026963     DOI: 10.1097/RLU.0b013e3181c3619c

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

1.  Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.

Authors:  Rauf Haznedar; Sahika Z Akı; Ozgür U Akdemir; Zübeyde N Ozkurt; Ozcan Ceneli; Münci Yağcı; Gulsan T Sucak; Mustafa Unlü
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

2.  In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Authors:  Rama K Mishra; Changyong Wei; Richard C Hresko; Richa Bajpai; Monique Heitmeier; Shannon M Matulis; Ajay K Nooka; Steven T Rosen; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

Review 3.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

4.  Development of GLUT4-selective antagonists for multiple myeloma therapy.

Authors:  Changyong Wei; Richa Bajpai; Horrick Sharma; Monique Heitmeier; Atul D Jain; Shannon M Matulis; Ajay K Nooka; Rama K Mishra; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  Eur J Med Chem       Date:  2017-08-14       Impact factor: 6.514

5.  [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].

Authors:  M Bhutani; O Landgren
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

Review 6.  Role of FDG PET in the staging of multiple myeloma.

Authors:  Joao R T Vicentini; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2021-04-04       Impact factor: 2.199

7.  Role of whole-body 64-slice multidetector computed tomography in treatment planning for multiple myeloma.

Authors:  Ahmed Abdel Khalek Abdel Razek; Amany Ezzat; Emad Azmy; Nehal Tharwat
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

8.  The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.

Authors:  Shengming Deng; Bin Zhang; Yeye Zhou; Xin Xu; Jihui Li; Shibiao Sang; Wei Zhang
Journal:  Contrast Media Mol Imaging       Date:  2018-07-30       Impact factor: 3.161

9.  Monomethyltransferase SET8 facilitates hepatocellular carcinoma growth by enhancing aerobic glycolysis.

Authors:  Xiangyuan Chen; Xiaowei Ding; Qichao Wu; Jie Qi; Minmin Zhu; Changhong Miao
Journal:  Cell Death Dis       Date:  2019-04-05       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.